Soo Yeon Kim

Soo Yeon Kim

Auto-generated profile, based on publicly available information

Soo Yeon Kim

Department of Genomic Medicine, Seoul National University Hospital, Seoul, Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2020 in BMC Neurology
Verified
Journal Article
Open access
PDF file
JCJieun Choi
Jieun Choi
SKSoo Yeon Kim
Soo Yeon Kim
HKHunmin Kim
Hunmin Kim
BLByung Chan Lim
Byung Chan Lim
HHHee Hwang
Hee Hwang
JSJeon-Soo Shin
Jeon-Soo Shin
Background: The search for noninvasive biomarkers of neuroinflammation and neurodegeneration has focused on various neurological disorders, including epilepsy. We sought to determine whether α-synuclein and cytokines are correlated with the degree of neuroinflammation and/or neurodegeneration in children with epilepsy and with acquired demyelinating disorders of the central nervous system (CNS), as a prototype of autoimmune neuroinflammatory disorders.Methods: We analyzed serum and exosome levels of α-synuclein and serum proinflammatory and anti-inflammatory cytokines among 115 children with epilepsy and 10 acquired demyelinating disorders of the CNS and compared to 146 controls. Patients were enrolled prospectively and blood was obtained from patients within 48 h after acute afebrile seizure attacks or relapse of neurological symptoms. Acquired demyelinating disorders of the CNS include acute disseminated encephalomyelitis, multiple sclerosis, neuromyelitis optica spectrum disorders, and transverse myelitis. The controls were healthy age-matched children. The serum exosomes were extracted with ExoQuick exosome precipitation solution. Serum α-synuclein levels and serum levels of cytokines including IFN-β, IFN-γ, IL-1β, IL-6, IL-10 and TNF-α were measured using single and multiplex ELISA kits. Data were analyzed and compared with measures of disease severity, such as age at disease onset, duration of disease, and numbers of antiepileptic drug in use.Results: Serum α-synuclein levels were significantly increased in patients with epilepsy and acquired demyelinating disorders of the CNS compared to controls (both,p < 0.05) and showed correlation with measures of disease severity both in epilepsy (p < 0.05,r = 0.2132) and in acquired demyelinating disorders of the CNS (p < 0.05,r = 0.5892). Exosome α-synuclein showed a significant correlation with serum α-synuclein (p < 0.0001,r = 0.5915). Serum IL-1β levels were correlated only with the numbers of antiepileptic drug used in children with epilepsy (p < 0.001, r = 0.3428), suggesting drug resistant epilepsy.Conclusions: This is the first study in children demonstrating that serum α-synuclein levels were significantly increased in children with epilepsy and with acquired demyelinating disorders of the CNS and correlated with measures of disease severity. Serum IL-1β levels showed significant correlation only with drug resistance in children with epilepsy. Thus, these data support that serum levels of α-synuclein and IL-1β are potential prognostic biomarkers for disease severity in children with epilepsy.CNS, central nervous system.

21 December 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
SKSoo Yeon Kim
Soo Yeon Kim
SJSe Song Jang
Se Song Jang
HKHunmin Kim
Hunmin Kim
HHHee Hwang
Hee Hwang
JCJi Eun Choi
Ji Eun Choi
BLByung Chan Lim
Byung Chan Lim

2 February 2024 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
JYJihoon G. Yoon
Jihoon G. Yoon
SLSeungbok Lee
Seungbok Lee
JCJaeso Cho
Jaeso Cho
NKNarae Kim
Narae Kim
SKSheehyun Kim
Sheehyun Kim
JCJong-Hee Chae
Jong-Hee Chae
To date, approximately 50 short tandem repeat (STR) disorders have been identified; yet, clinical laboratories rarely conduct STR analysis on exomes. To assess its diagnostic value, we analyzed STRs in 6099 exomes from 2510 families with mostly suspected neurogenetic disorders. We employed ExpansionHunter and REViewer to detect pathogenic repeat expansions, confirming them using orthogonal methods. Genotype-phenotype correlations led to the diagnosis of thirteen individuals in seven previously undiagnosed families, identifying three autosomal dominant disorders: dentatorubral-pallidoluysian atrophy (n = 3), spinocerebellar ataxia type 7 (n = 2), and myotonic dystrophy type 1 (n = 2), resulting in a diagnostic gain of 0.28% (7/2510). Additionally, we found expanded ATXN1 alleles (≥39 repeats) with varying patterns of CAT interruptions in twelve individuals, accounting for approximately 0.19% in the Korean population. Our study underscores the importance of integrating STR analysis into exome sequencing pipeline, broadening the application of exome sequencing for STR assessments.

1 May 2018 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
DYDallah Yoo
Dallah Yoo
HKHan Joon Kim
Han Joon Kim
JLJin Sook Lee
Jin Sook Lee
SLSangmoon Lee
Sangmoon Lee
SKSoo Yeon Kim
Soo Yeon Kim
BJBeomseok Jeon
Beomseok Jeon

20 March 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SKSoo Yeon Kim
Soo Yeon Kim
BLByung Chan Lim
Byung Chan Lim
JLJin Sook Lee
Jin Sook Lee
WKWoo Joong Kim
Woo Joong Kim
HKHyuna Kim
Hyuna Kim
JCJong-Hee Chae
Jong-Hee Chae
The Korean Undiagnosed Diseases Program (KUDP) was launched in January 2017 as a one-year pilot project to address the increasing global interest in patients with undiagnosed rare diseases. The purpose of this paper is to summarize the project results and emphasize the unmet research needs among patients with undiagnosed rare diseases in Korea. Patient enrollment, assessment, and diagnostic processes were determined by the KUDP clinical expert consortium. Patients followed a diagnostic workflow after being categorized into one of four groups: I) insufficient clinical information or lack of standard diagnostic processes; II) undiagnosed due to low disease awareness; III) clinically diagnosed but unconfirmed genetically due to genetic heterogeneities; or IV) unknown disease due to complex, atypical clinical presentations. After excluding two patients from group I, 97 patients were enrolled, including 10 in group II, 67 in group III, and 20 in group IV. Most of them (92 of 97, 94.8%) were pediatric patients (< 18 years old) and 59 (60.8%) were male. The primary symptoms for 80 patients (82.5%) were neurologic. During the one-year pilot study, 72 patients completed a diagnostic assessment including clinical and molecular genetic analyses; some patients also underwent pathological or biochemical analysis. Twenty-eight of these patients (28/72, 38.9%) achieved molecular genetic diagnosis. Thirteen patients were diagnosed based on traditional tests, including biochemical assay, single or targeted genetic analysis, and chromosomal microarray. We performed whole exome sequencing on 52 patients, among whom 15 (28.8%, 15/52) reached a final diagnosis. One new disorder was identified via international collaboration. Using an efficient clinical diagnostic workflow, this KUDP pilot study resulted in a fair diagnostic success rate, improving the potential for additional diagnoses and new scientific discovery of complex and rare diseases. KUDP also satisfied unmet needs for rare diseases with multisystem involvement, highlighting the value of emerging genomic technologies for further research into rare and still-undiagnosed conditions.

9 December 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SKSoo Yeon Kim
Soo Yeon Kim
YSYoungkyu Shim
Youngkyu Shim
YKYoung Joon Ko
Young Joon Ko
SPSoojin Park
Soojin Park
SJSe Song Jang
Se Song Jang
JCJong-Hee Chae
Jong-Hee Chae
Background: GNAO1 encephalopathy is a rare neurodevelopmental disorder characterized by distinct movement presentations and early onset epileptic encephalopathy. Here, we report the in-depth phenotyping of genetically confirmed patients with GNAO1 encephalopathy, focusing on movement presentations. Results: Six patients who participated in Korean Undiagnosed Disease Program were diagnosed to have pathogenic or likely pathogenic variants in GNAO1 using whole exome sequencing. All medical records and personal video clips were analyzed with a literature review. Three of the 6 patients were male. Median follow-up duration was 41 months (range 7–78 months) and age at last examination was 7.4 years (range 3.3–16.9 years). Initial complaints were hypotonia or developmental delay in 5 and right-hand clumsiness in 1 patient, which were noticed at median age of 3 months (range 0–75 months). All patients showed global developmental delay and 4 had severely retarded development. Five patients (5/6, 83.3%) had many different movement symptoms with various onset and progression. The symptoms included stereotyped hands movement, non-epileptic myoclonus, dyskinesia, dystonia and choreoathetosis. Whole exome sequencing identified 6 different variants in GNAO1. Three were novel de novo variants and atypical presentation was noted in a patient. One variant turned out to be inherited from patient’s mother who had mosaic variant. Distinct and characteristics movement phenotypes in patients with variant p.Glu246Lys and p.Arg209His were elucidated by in-depth phenotyping and literature review. Conclusions: We reported 6 patients with GNAO1 encephalopathy showing an extremely diverse clinical spectrum on video. Some characteristic movement features identified by careful inspection may also provide important diagnostic insight and practice guidelines.